Oncolytics Biotech Inc.
ONCY
$0.90
$0.022.32%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -134.63% | 4.37% | 18.64% | 18.15% | -31.95% |
| Total Depreciation and Amortization | -0.59% | 0.44% | 18.18% | -25.71% | 7.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 523.87% | -10.53% | -12.20% | 253.15% | 134.66% |
| Change in Net Operating Assets | 1,303.72% | 73.77% | 13.23% | -121.67% | 1,914.26% |
| Cash from Operations | -22.12% | 12.66% | 19.22% | -58.21% | 28.91% |
| Capital Expenditure | -- | -- | -- | 81.70% | 79.26% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | 81.70% | 79.26% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.98% | 0.97% | -3.00% | -25.00% | -23.08% |
| Issuance of Common Stock | -29.94% | 1.59% | 72.62% | 1,157.14% | -86.78% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 77.23% | -262.55% | -39.05% | 55.53% | -190.08% |
| Cash from Financing | -22.63% | -5.38% | 72.05% | 1,981.15% | -108.79% |
| Foreign Exchange rate Adjustments | 142.68% | -1,837.50% | -103.53% | 488.45% | -187.65% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -237.42% | -9.91% | 82.95% | 32.18% | -10.86% |